Kilitch Drugs (India) Limited (KILITCH) - Total Assets
Based on the latest financial reports, Kilitch Drugs (India) Limited (KILITCH) holds total assets worth Rs3.99 Billion INR (≈ $43.11 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kilitch Drugs (India) Limited - Total Assets Trend (2006–2025)
This chart illustrates how Kilitch Drugs (India) Limited's total assets have evolved over time, based on quarterly financial data. Also see Kilitch Drugs (India) Limited market capitalisation for the company's overall valuation and market capitalisation.
Kilitch Drugs (India) Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Kilitch Drugs (India) Limited's total assets of Rs3.99 Billion consist of 55.6% current assets and 44.4% non-current assets. Review total liabilities of Kilitch Drugs (India) Limited to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs28.69 Million | 3.1% |
| Accounts Receivable | Rs847.39 Million | 27.1% |
| Inventory | Rs153.10 Million | 4.9% |
| Property, Plant & Equipment | Rs928.19 Million | 29.7% |
| Intangible Assets | Rs188.87 Million | 6.0% |
| Goodwill | Rs185.36 Million | 5.9% |
Asset Composition Trend (2006–2025)
This chart illustrates how Kilitch Drugs (India) Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See KILITCH stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kilitch Drugs (India) Limited's current assets represent 55.6% of total assets in 2025, an increase from 33.3% in 2006.
- Cash Position: Cash and equivalents constituted 3.1% of total assets in 2025, up from 0.5% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.7% of total assets.
Kilitch Drugs (India) Limited Competitors by Total Assets
Key competitors of Kilitch Drugs (India) Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Kilitch Drugs (India) Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.53 | 2.09 | 1.01 |
| Quick Ratio | 2.37 | 2.01 | 0.97 |
| Cash Ratio | 0.40 | 0.08 | 0.00 |
| Working Capital | Rs1.26 Billion | Rs768.97 Million | Rs3.47 Million |
Kilitch Drugs (India) Limited - Advanced Valuation Insights
This section examines the relationship between Kilitch Drugs (India) Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.11 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 30.3% |
| Total Assets | Rs3.13 Billion |
| Market Capitalization | $72.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kilitch Drugs (India) Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Kilitch Drugs (India) Limited's assets grew by 30.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kilitch Drugs (India) Limited (2006–2025)
The table below shows the annual total assets of Kilitch Drugs (India) Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs3.13 Billion ≈ $33.83 Million |
+30.29% |
| 2024-03-31 | Rs2.40 Billion ≈ $25.96 Million |
+9.36% |
| 2023-03-31 | Rs2.20 Billion ≈ $23.74 Million |
+4.61% |
| 2022-03-31 | Rs2.10 Billion ≈ $22.69 Million |
+3.28% |
| 2021-03-31 | Rs2.03 Billion ≈ $21.97 Million |
+42.25% |
| 2020-03-31 | Rs1.43 Billion ≈ $15.45 Million |
-0.58% |
| 2019-03-31 | Rs1.44 Billion ≈ $15.54 Million |
+12.52% |
| 2018-03-31 | Rs1.28 Billion ≈ $13.81 Million |
+13.09% |
| 2017-03-31 | Rs1.13 Billion ≈ $12.21 Million |
-3.25% |
| 2016-03-31 | Rs1.17 Billion ≈ $12.62 Million |
-7.93% |
| 2015-03-31 | Rs1.27 Billion ≈ $13.71 Million |
-1.81% |
| 2014-03-31 | Rs1.29 Billion ≈ $13.96 Million |
-5.70% |
| 2013-03-31 | Rs1.37 Billion ≈ $14.80 Million |
-22.64% |
| 2012-03-31 | Rs1.77 Billion ≈ $19.13 Million |
+9.73% |
| 2011-03-31 | Rs1.61 Billion ≈ $17.44 Million |
+16.62% |
| 2010-03-31 | Rs1.38 Billion ≈ $14.95 Million |
-3.16% |
| 2009-03-31 | Rs1.43 Billion ≈ $15.44 Million |
+8.58% |
| 2008-03-31 | Rs1.31 Billion ≈ $14.22 Million |
+86.94% |
| 2007-03-31 | Rs703.40 Million ≈ $7.61 Million |
+58.88% |
| 2006-03-31 | Rs442.74 Million ≈ $4.79 Million |
-- |
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, ant… Read more